slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 22,321-22,350
Pages 885
Rows per page 30
Arc
22,321-22,350 of 26,550
18
Includes both internal cash position and public market trading data for BJSX.Bluejay | Investor Presentation Deck | 20 slides · Bluejay Diagnostics
Pitch deck Investor relations Beat · Financial Highlights1 hit
04
Uses a visual metaphor of fluid dynamics (beakers and spheres) to explain viscosity reduction.Comera | Investor Presentation Deck | 16 slides · Comera
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide uses a hub-and-spoke visual structure to categorize benefits by stakeholder group.Comera | Investor Presentation Deck | 16 slides · Comera
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
06
Includes a callout highlighting J&J's Darzalex Faspro achieving 85% conversion in under 2 years.Comera | Investor Presentation Deck | 16 slides · Comera
Pitch deck Investor relations Beat · Evidence & ProofLoop · Golden Circle1 hit
07
The slide uses a hub-and-spoke diagram to illustrate the integration of three core components: Expert Engineering, Viscosity Reducing Excipients, and Computational Modeling.Comera | Investor Presentation Deck | 16 slides · Comera
Pitch deck Investor relations Beat · Evidence & ProofLoop · Golden Circle1 hit
08
The slide features a screenshot of a specific scientific paper as evidence of peer-reviewed validation.Comera | Investor Presentation Deck | 16 slides · Comera
Pitch deck Investor relations Beat · Evidence & ProofLoop · Golden Circle1 hit
09
The slide highlights a 77% viscosity reduction for Infliximab and a 45-78% reduction for Ipilimumab.Comera | Investor Presentation Deck | 16 slides · Comera
Pitch deck Investor relations Beat · Evidence & ProofLoop · Golden Circle1 hit
10
The slide features two distinct research papers from the Journal of Pharmaceutical Sciences, showcasing data on viscosity reduction (infliximab, ipilimumab) and pharmacokinetic studies.Comera | Investor Presentation Deck | 16 slides · Comera
Pitch deck Investor relations Beat · Evidence & ProofLoop · Golden Circle1 hit
11
Includes three distinct data panels: bar chart for viscosity, line charts for stability (SEC and IEX), and a dose-response curve for potency.Comera | Investor Presentation Deck | 16 slides · Comera
Pitch deck Investor relations Beat · Evidence & ProofLoop · Golden Circle1 hit
12
The table uses green checkmarks for Comera and grey checkmarks for competitors, highlighting Comera's unique combination of all three advantages.Comera | Investor Presentation Deck | 16 slides · Comera
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Golden Circle1 hit
13
Comera | Investor Presentation Deck | 16 slidesComera | Investor Presentation Deck | 16 slides · Comera
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Golden Circle1 hit
14
The slide lists 11 US patents and 12 international patents, totaling 23 distinct patent identifiers.Comera | Investor Presentation Deck | 16 slides · Comera
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Golden Circle1 hit
05
This is a section divider or introductory slide for the product solution.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
06
The slide details a specific corporate partnership agreement.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
07
The slide uses a side-by-side comparison structure to detail the status and upcoming milestones for two distinct clinical programs.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
08
Equillium | Investor Presentation Deck | 32 slidesEquillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
09
Includes a diagram illustrating cytokine-receptor binding and downstream signaling.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The slide highlights the structural commonality of the γC receptor across multiple cytokines, positioning it as a therapeutic target.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
The slide uses a structural biology approach to explain the mechanism of action for their therapeutic platform.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
The slide uses a biological process diagram to illustrate how the inhibitor prevents the dimerization of private receptors with the shared receptor.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
The slide uses a visual comparison framework to illustrate the mechanism of action and therapeutic benefits.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
16
Equillium | Investor Presentation Deck | 32 slidesEquillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
17
The slide uses a four-column structure to explain the target, molecular nature, preclinical results, and clinical status.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
18
The slide uses a column-based layout to compare four distinct medical conditions, each with specific patient counts and development milestones.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
19
The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
20
Includes before/after patient photos and comparative data against Mogamulizumab.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
Equillium | Investor Presentation Deck | 32 slidesEquillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
22
The slide uses a circular process diagram to show the feedback loop of cytokines and immune cells leading to hair loss.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
Includes visual longitudinal data (photos) and quantitative bar chart data.Equillium | Investor Presentation Deck | 32 slides · Equillium
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit